Skin substitute billing in the office setting: a practice manager's guide

Start with the setting

How a skin substitute is paid depends heavily on where it is applied. Physician offices, hospital outpatient departments, and ambulatory surgery centers each follow different payment methods, and the same product can be reimbursed very differently across them. Before adding any cellular or tissue-based product (CTP) to your formulary, confirm which setting you bill under and which payment method applies to that setting for the payer in question.

In the office setting, Medicare has been moving toward a more standardized approach to skin substitute payment, which changes the math that used to favor some products over others. Commercial payers and Medicare Advantage plans have their own policies and often their own prior authorization requirements. Assume nothing carries over between payers.

For what changed in Medicare payment and coverage on 1 January 2026, see our guide to skin substitute payment and coverage in 2026.

Verify benefits for every patient, every product

A benefit verification is not a formality. For skin substitutes it should answer, in writing:

• Is this product covered for this diagnosis in this setting?
• Is prior authorization required, and for how many applications?
• What is the maximum number of applications the payer allows per wound or per episode?
• What is the patient's deductible, coinsurance, and out-of-pocket position?
• Are there step-therapy or documentation-of-failed-conservative-care requirements?

Store the answer in the chart with the date and reference number. If a claim is later questioned, the verification is the first thing you will want to produce.

Understand application limits

Most coverage policies cap the number of skin substitute applications per wound within a defined period. Some cap total applications across products. The chart should show a running count, and the plan of care should state the clinical basis for each additional application, typically documented wound-area reduction that is progressing but not yet complete.

Where a wound is not responding after a defined number of applications, most policies expect a change in approach rather than continued applications. Build a stop-and-reassess point into your protocol so the decision is clinical and documented rather than discovered at the denial stage.

Discarded product (wastage) in 2026

Skin substitutes come in fixed sizes, and wounds do not. How the unused part is handled changed for Medicare on 1 January 2026.

Since that date, Medicare pays most skin substitutes as incident-to supplies. This covers every product that is not licensed under a biologics license application (BLA) under section 351 of the Public Health Service Act. For these non-BLA products, CMS says:

• Only the administered portion is payable.
• It is not appropriate to bill Medicare for discarded units under any circumstance. Discarded units may not be billed with the JW modifier or added to the administered amount.
• The JW and JZ modifiers are not used. They apply only to drugs and biologicals that are separately payable under Part B.

Some MACs reject these claims outright. First Coast, for example, states that skin substitute claims with JW or JZ for dates of service on or after 1 January 2026 will be rejected.

Products licensed under a BLA are still paid as biologicals under the average sales price method. Confirm a product's FDA status with the manufacturer before you bill it.

Medicare Advantage and commercial plans set their own rules, and some may still ask for discarded amounts to be reported. Check each plan's current policy.

The chart still has to match the claim. Record the product, its size, the lot number and the amount applied, along with the wound measurements. For Medicare non-BLA products, bill only the amount applied.

Keep lot and serial numbers

Every graft shipped carries a lot or serial number. Record it in the procedure note and maintain a log that ties each unit received to a specific patient and date of service. Auditors reconcile purchase records against claims, and a clean log is the fastest way through that review.

Match the codes to the note

The application procedure code, the product code, the diagnosis codes, and the units should all tell the same story as the narrative note. Common mismatches include a wound-size range in the procedure code that does not match the documented measurements, a diagnosis that does not support medical necessity for the product, or units that do not reconcile with the amount applied. Whoever submits your claims, in-house or outsourced, should be checking these four points against the note before submission.

Plan for denials

Even well-run clinics see denials. What matters is response time and pattern recognition. Review every denial reason, appeal where the documentation supports it, and log the reason. If the same reason recurs, the fix is usually upstream, in the verification step or the note template, not in the appeal.

Summary

Skin substitute billing rewards clinics that treat the administrative work as part of the clinical protocol: verify before applying, document measurements and the amount applied every time, track applications against limits, and keep lot records that reconcile. A distributor that handles verification, authorization, and claims can take most of this off the front desk, but the chart itself is still the clinic's responsibility.

Sources

Checked 17 Oct 2026.

• CMS JW and JZ modifier FAQs, question 9. Non-BLA skin substitutes: only the administered portion is payable; JW and JZ not used.
• CMS fact sheet: CY 2026 Physician Fee Schedule final rule. Skin substitutes paid as incident-to supplies from 1 January 2026.
• CY 2026 Physician Fee Schedule final rule, 90 FR 49266. BLA products remain under section 1847A.
• First Coast: non-sheet skin substitute payment and documentation (3 Sep 2026). JW and JZ claims rejected.